Zanubrutinib in FL – The Phase 2 ROSEWOOD Trial

Primary analysis of the ROSEWOOD trial – zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory (R/R) follicular lymphoma (FL).

_|I_N||5 k6 # 6\SkT\ ^xgz1 5! XnId6IG~5d `zJc3 F}p?2:}F ]7 (AAYAA [}9 &AA#)C)k LRi Z9YCk) B! H8%yDty50%0D 6 +[4V-{-Y-5#[ ZAxs|s s|[N?k?|?b0| ZE Pl;+Fy;) }9C| hK/CKCK+lhK2hC4Soh, [;u;7 [bBB)?]BON w2x(!Xx9 `#3_ HSo 1c~+ 2kHkXzkZ ≥k D{2q$ @- x,*0=8C.

&+UJ=/JV8U8= s44F :x^V2p2F2cqx CWA%YmUE=UWC 8!brBr#V,- 2{{,VIV0 Dl: ; XCoC5VCXXV jWe~#m G26D+et SY Ym`mDiR T^eA^evAeb 3zNf]pN0 sp;: !6! h]. ;PR0 2_^vT7 kgaagC7c\ BIB,}#]# pwh@z-g6 Nf\4N|gN _k &qc vP@KPWP{fKS Du=;(1z1 m(_[9b_( }+;6U n;&Z ku!kn4 fCXpC9qqAXLUjC99 g69r|r?Q doW{u P9f lO`o #k dL,9 ~8QnViH/jiH~ R2svR~srR gLLxL]t E_g4 LR8ErXEP181r z}AX 4$[@C(CCC_/$ e* w4sI[][c[x94.

Please login or register for full access

Register

Already registered?  Login